Nature's Sunshine Products (NATR) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nature's Sunshine Products (NATR) has outperformed Entrada Therapeutics (TRDA) over the past year, losing 51.8% versus a loss of 57.0%. Over five years, NATR leads with a -40.4% price change compared with -85.0% for TRDA. Nature's Sunshine Products is the larger company by market cap ($176.4 million vs $170.3 million), about 1.0 times the size.
Nature's Sunshine Products converts more of its revenue into profit, with a net margin of 4.1% versus -565.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NATR | TRDA |
|---|---|---|
| Share price | $10.18 | $4.35 |
| Market cap | $176.41M | $170.30M |
| 1-day change | +0.10% | -6.25% |
| YTD return | -52.83% | -57.68% |
| 1-year return | -51.84% | -56.97% |
| 5-year return | -40.40% | -84.95% |
| P/E ratio (TTM) | 12.41 | — |
| Forward P/E | 10.77 | — |
| EPS (TTM) | $0.82 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $480.14M | $25.42M |
| Revenue growth (YoY) | +5.67% | -87.94% |
| Net income (latest FY) | $19.52M | $-143.75M |
| Gross margin | 72.42% | — |
| Operating margin | 5.15% | -621.13% |
| Net margin | 4.07% | -565.48% |
| 52-week high | $28.14 | $16.45 |
| 52-week low | $9.38 | $4.11 |
| Distance from 52-week high | -63.82% | -73.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +62.08% | +308.05% |
| Average volume | 168.24K | 401.15K |
| Shares outstanding | 17.33M | 39.15M |
| Employees | 806 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nature's Sunshine Products is more profitable, keeping 4.1 cents of every revenue dollar as net income versus -565.5 cents for Entrada Therapeutics.
- Nature's Sunshine Products grew revenue faster in its latest fiscal year (+5.67% vs -87.94%).
About Nature's Sunshine Products
NATR stock →Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company distributes general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision; and immune products to support and strengthen the human immune system.
Health Care · Biotechnology: Pharmaceutical Preparations · 806 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
NATR vs TRDA FAQ
Which is bigger, Nature's Sunshine Products or Entrada Therapeutics?
Nature's Sunshine Products (NATR) is larger, with a market capitalization of $176.41M compared with $170.30M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, NATR or TRDA?
NATR returned -51.84% over the past 12 months, compared with -56.97% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are Nature's Sunshine Products and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.